

REMARKS

Claim 16 has been cancelled from the present application without prejudice to re-filing in a continuation application. New claims 20 and 21 have been added. Claims 1 – 15, and 17 - 21 are currently pending.

Objections

Claims 1 – 19 were objected to because of informalities. Claims 1, 6, 7, 8, and 11- 14 have been amended to remove an extra "-" in chemical names. Support for the amendment to claims 1, 6, 7, 8, and 11 - 14 can be found in the specification at pages 4 – 6. Claims 2 and 6 have been amended to replace "Ri" with "R¹". Claim 3 has been amended to replace "R" with "R¹". Support for the amendments to claims 2, 3, and 6 can be found in the specification at pages 4 – 6. Claims 1 and 14 have been amended to correct typographical errors.

35 U.S.C. § 112

Claim 14 was rejected under 35 U.S.C. § 112, second paragraph because the Examiner contended that while the claim is directed to a process for preparing a compound of formula 1 where R¹ is a number of substituents, the claim recites the preparation of a compound wherein R¹ chloro. Applicants respectfully disagree. Claim 14 as originally filed recites the preparation of compound of formula 1 wherein R¹ is chloro, amino, phenylamino, 2-pyridylamino, 3,4-dimethyl-5-isoxazolylamino and 5-methyl-3-isoxazolylamino. However, for clarity, claim 14 has been amended to recite preparation of a compound wherein R¹ is amino, phenylamino, 2-pyridylamino, 3,4-dimethyl-5-isoxazolylamino and 5-methyl-3-isoxazolylamino. New claim 20 is directed to the preparation of a compound of formula 1 wherein R¹ is chloro. Support for the amendment to claim 14 and support for new claims 20 and 21 can be found in the specification at pages 4 – 6, originally filed claim 14, and in the Examples.


Claim 16 was rejected under 35 U.S.C. § 112. Claim 16 has been cancelled. Therefore, the rejection is moot as to claim 16.

It is respectfully submitted that the present application is in condition for allowance. An early consideration and notice of allowance are earnestly solicited.

Applicants hereby request a 1-month extension of time to extend the response period up to and including 20 June 2007. The Commissioner is hereby authorized to charge such fees and any other fees required or credit any overpayment to Deposit Account No. 07-1392]

Respectfully submitted,

Dated: June 20, 2007


Karen L. Prus

GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive, PO Box 13398
Research Triangle Park, NC 27709-3398
Telephone: 919-483-2192
Fax: 919-483-7988

Attorney for Applicant
Reg. No. 39,337